Marco Puzzoni

List of Publications by Year in descending order

64 papers	882 citations	471477 17 h-index	526264 27 g-index
66 all docs	66 docs citations	66 times ranked	1676 citing authors

#	Article	IF	Citations
1	Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer.. Journal of Clinical Oncology, 2022, 40, 182-182.	1.6	0
2	HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples. British Journal of Cancer, 2022, 126, 1783-1794.	6.4	12
3	Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients. Frontiers in Oncology, 2022, 12, 852583.	2.8	6
4	How to improve metastatic pancreatic ductal adenocarcinoma patientsâ€™ selection: Between clinical trials and the real-world. World Journal of Clinical Oncology, 2022, 13, 417-422.	2.3	0
5	Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e16301-e16301.	1.6	0
6	Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. European Journal of Cancer, 2022, 171, 232-241.	2.8	7
7	Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.. Journal of Clinical Oncology, 2022, 40, 4153-4153.	1.6	0
8	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Tumori, 2021, 107, 550-555.	1.1	5
9	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Critical Reviews in Oncology/Hematology, 2021, 157, 103167.	4.4	30
10	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. Targeted Oncology, 2021, 16, 517-527.	3.6	7
11	Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 3577-3577.	1.6	2
12	Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. Clinical Colorectal Cancer, 2021, , .	2.3	0
13	BRCA-mutant pancreatic ductal adenocarcinoma. British Journal of Cancer, 2021, 125, 1321-1332.	6.4	15
14	Molecular-driven treatment for biliary tract cancer: the promising turning point. Expert Review of Anticancer Therapy, 2021, 21, 1253-1264.	2.4	0
15	Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Science, 2021, 112, 4819-4833.	3.9	4
16	Results of the observational prospective RealFLOT study. BMC Cancer, 2021, 21, 1086.	2.6	17
17	Cholangiocarcinoma: new perspectives for new horizons. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1367-1383.	3.0	13
18	Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2021, 25, 987-1005.	3.4	8

#	Article	IF	Citations
19	Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients?. Future Oncology, 2020, 16, 4337-4339.	2.4	11
20	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. Clinical Medicine Insights: Oncology, 2020, 14, 117955492094669.	1.3	9
21	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1214.	3.7	26
22	From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. Cancers, 2020, 12, 1330.	3.7	7
23	Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression. International Journal of Molecular Sciences, 2020, 21, 4494.	4.1	24
24	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology, 2020, 15, 115-126.	3.6	15
25	Immune Checkpoint Inhibitors in the Treatment of HCC. Frontiers in Oncology, 2020, 10, 601240.	2.8	77
26	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. European Journal of Cancer, 2020, 133, 66-73.	2.8	19
27	Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis.. Journal of Clinical Oncology, 2020, 38, 660-660.	1.6	3
28	Perioperative FLOT in resectable gastric cancer: Italian real-world data from the RealFLOT study.. Journal of Clinical Oncology, 2020, 38, 300-300.	1.6	0
29	Perioperative FLOT in elderly patients with resectable gastric cancer: Subgroup analysis from the observational RealFLOT study.. Journal of Clinical Oncology, 2020, 38, 4548-4548.	1.6	0
30	Clustered protocadherins methylation alterations in cancer. Clinical Epigenetics, 2019, 11, 100.	4.1	33
31	Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine. Annals of Oncology, 2019, 30, iv63.	1.2	0
32	A new prognostic score for biliary tract cancer: a multicenter experience. Annals of Oncology, 2019, 30, iv92.	1.2	0
33	Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab. Annals of Oncology, 2019, 30, v226.	1.2	0
34	New therapeutic targets in pancreatic cancer. Cancer Treatment Reviews, 2019, 81, 101926.	7.7	74
35	Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials . OncoTargets and Therapy, 2019, Volume 12, 2981-2988.	2.0	26
36	RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.. Journal of Clinical Oncology, 2019, 37, e15663-e15663.	1.6	0

#	Article	IF	Citations
37	BRAF-mutant colorectal cancer, a different breed evolving. Expert Review of Molecular Diagnostics, 2018, 18, 499-512.	3.1	19
38	The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome. Annals of Oncology, 2018, 29, viii264.	1.2	0
39	P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. Annals of Oncology, 2018, 29, v58-v59.	1.2	0
40	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: TheÂTOREADOR Study. Clinical Colorectal Cancer, 2018, 17, e601-e615.	2.3	18
41	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. Critical Reviews in Oncology/Hematology, 2017, 110, 106-116.	4.4	33
42	Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?. European Journal of Endocrinology, 2017, 177, 85-92.	3.7	23
43	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology, 2017, 115, 1-12.	4.4	26
44	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. British Journal of Cancer, 2017, 117, 315-321.	6.4	19
45	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. Scientific Reports, 2017, 7, 45703.	3.3	22
46	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	3.1	85
47	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2017, 120, 13-21.	4.4	56
48	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 T 117, 1099-1104.	6.4	11
49	Management of breakthrough cancer pain in patients with oral mucositis. Annals of Oncology, 2017, 28, vi104.	1.2	0
50	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab. Annals of Oncology, 2017, 28, vi9-vi10.	1.2	0
51	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. Oncotarget, 2017, 8, 66699-66708.	1.8	11
52	The role of sidedness, EGFR gene copy number (GCN) and EGFR promoter methylation in RAS/BRAF wild type (WT) colorectal cancer (CRC) patients receiving irinotecan/cetuximab.. Journal of Clinical Oncology, 2017, 35, 628-628.	1.6	0
53	Prognostic neutrophil-to-lymphocyte ratio in head and neck cancer: A single center experience.. Journal of Clinical Oncology, 2017, 35, e17540-e17540.	1.6	0
54	Effective combinatorial immunotherapy for castration-resistant prostate cancer: new future chance?. Translational Cancer Research, 2017, 6, S1014-S1017.	1.0	0

#	Article	IF	Citations
55	Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. Journal of Cardiovascular Medicine, 2016, 17, e12-e18.	1.5	78
56	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. Targeted Oncology, 2016, 11, 593-603.	3.6	14
57	REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol). Annals of Oncology, 2016, 27, iv53.	1.2	0
58	Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK). Annals of Oncology, 2016, 27, vi205.	1.2	0
59	Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management.. Journal of Clinical Oncology, 2016, 34, e15004-e15004.	1.6	0
60	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis.. Journal of Clinical Oncology, 2016, 34, e15116-e15116.	1.6	0
61	INTEGRATE phase II trial: regorafenib vs. placebo in pretreated metastatic gastric cancer patientsâ€"is there anything new?. Translational Cancer Research, 2016, 5, S1047-S1050.	1.0	0
62	Clinical Outcome of Patients With Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. Annals of Oncology, 2015, 26, vi50.	1.2	2
63	A single institution survey on prevalence and management of severe cancer pain in patients with cancer of different sites. Annals of Oncology, 2015, 26, vi116.	1.2	1
64	The distinctive molecular, pathological and clinical characteristics ofBRAF-mutant colorectal tumors. Expert Review of Molecular Diagnostics, 2015, 15, 979-987.	3.1	14